National and Kapodistrian University of Athens
Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα
Abstract
dc:descriptionSummary: TGF-β1 is an important pre-fibrinogenic cytokine, which is produced by the non-parenchymal liver cells, activates the hepatic asteroid cells and has been involved in the pathogenesis of liver fibrosis. For that reason, its role in the evolution of liver fibrosis has been studied for many years in patients with chronic hepatitis C (CHC) as well as with chronic hepatitis B. The purpose of this dissertation was to study the serum TGF-β1 levels, in association with liver fibrosis and to examine their change according to treatment response and their value as a predictive index in patients with CHC under antiviral treatment.Eighty four patients were included in the study (average age 46 years- old, 44 men, 40 women) with CHC belonging to all known HCV genotypes and were treated with pegylated interferon plus ribavirin. Liver fibrosis was estimated non-invasively with liver transient elastography. TGF-β1 levels were measured before and at the end of follow-up and 6 months after the completion of antiviral therapy using a standard immunoassay.TGF-β1 levels were not associated with epidemiological, biochemical or virological parameters. Univariate analysis showed association between antiviral treatment, age and white blood count, but not with the initial TGF-β1 levels. For patients with sustained virological response (SVR) TGF-β1 levels were significantly decreased at the end (12.327 pg/ml, p<0.0001) and 6 months after the completion of antiviral therapy (13.555 pg/ml, p=0.007) compared to baseline values (17.166 pg/ml), but not in patients showing relapse (11.487 vs 12.241 or 9.648 pg/ml, p=0.814 or p=0.344) or in patients showing non-response (16.319 vs 11.362 or 11.977 pg/ml, p=0.227 or p=0.695). There was no association between TGF-β1 and degree of liver fibrosis as estimated with transient elastography at baseline (p=0.29).In conclusion, our results shown that TGF-β1 displayed significant decrease in CHC patients with SVR to antiviral therapy. TGF-β1 levels are not associated with degree of liver fibrosis or to response to antiviral treatment.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kotsiri, Ioanna
- Κοτσίρη, Ιωάννα
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/37543